便头部空间中的易挥发性有机化合物与典型的基于症状的亚型无关
R Van Vorstenbosch1,2,3, M Skawinski2,3, D Jonkers3,4
1Institute of Risk Assessment Sciences, Population Health Sciences, Utrecht University, Utrecht, The Netherlands.
Journal of breath research
|December 2, 2025
概括
研究人员在便中确定了特定的挥发性有机化合物 (VOC),以区分刺激性肠综合征 (IBS) 患者和健康人. 然而,这些代谢特征与基于便模式的当前IBS亚型不一致.
科学领域:
- 胃肠道学和新陈代谢学
- 微生物组研究 微生物组研究
- 生物标志物发现发现
背景情况:
- 刺激性肠综合征 (IBS) 是一种通过基于症状的罗马标准诊断的肠-大脑相互作用障碍,该标准根据便模式将患者分类为亚型.
- 目前这些IBS亚型的生物学基础尚不清楚,需要新的方法来了解疾病异质性.
- 便中的挥发性有机化合物 (VOC) 为肠道微生物和宿主肠道过程提供了一个窗口,可能揭示IBS的病理生理差异.
研究的目的:
- 调查便VOC概况是否可以将IBS患者与健康对照区分开来.
- 探索便VOC档案与现有的基于罗马III的IBS亚型之间的关联.
- 评估VOC分析作为IBS特征的非侵入性工具的潜力.
主要方法:
- 在164名IBS患者和143名健康对照人群中,使用气色谱-质谱分析对便头部空间的VOC进行了分析.
- 随机森林模型被用于数据归算和识别歧视性VOC.
- 部分最小平方回归对便水含量进行了校正,并调整了MANOVA评估与罗马III亚型的关联.
主要成果:
- 与对照组相比,在IBS患者中,共有39个VOC被显著改变.
- 一个分类模型实现了0.82的曲线下的面积,表明IBS患者和健康个体之间的强有力的分离.
- 在便VOC资料和基于罗马III的IBS亚型之间没有发现显著的关联.
结论:
- 便VOC分析是一种有前途的非侵入性方法,用于研究IBS并将患者与健康个体区分开来.
- 目前以便为基础的IBS亚型缺乏明确的代谢基础,因为缺乏与VOC档案的关联.
- 未来的研究应该将VOC分析与其他omics数据相结合,以开发针对个性化疗法的生物学相关IBS分类.
关键词:
罗马标准 罗马标准 罗马标准便头部空间的便.气色谱学 质谱学 (GC-MS) 气色谱学刺激性肠综合征 (IBS) 是一种机器学习是机器学习.预测 预测 预测 预测这就是volatolomics.更多相关视频
相关概念视频
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
710
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
710
Irritable Bowel Syndrome I: Introduction
893
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
893
Chronic Bowel Disorders: Introduction
734
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
734
Drugs for Treatment of Diarrhea-Predominant IBS
599
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
599
Irritable Bowel Syndrome III: Medical and Nursing Management
617
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
617
Drugs for Treatment of Constipation-Predominant IBS
680
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
680


